NASDAQ:NBRV - Nabriva Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nabriva Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.51 -0.05 (-3.21 %) (As of 02/24/2020 09:50 AM ET) Add Compare Today's Range$1.50Now: $1.51▼$1.5550-Day Range$1.21MA: $1.40▼$1.6252-Week Range$1.16Now: $1.51▼$3.27Volume100,402 shsAverage Volume941,520 shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBRV Previous Symbol CUSIPN/A CIK1641640 Webhttp://www.nabriva.com/ Phone353-1649-2000Debt Debt-to-Equity Ratio0.87 Current Ratio5.81 Quick Ratio5.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.66 million Price / Sales147.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book15.10Profitability EPS (Most Recent Fiscal Year)($1.63) Net Income$-114,780,000.00 Net Margins-910.45% Return on Equity-171.36% Return on Assets-93.30%Miscellaneous EmployeesN/A Outstanding Shares945,450,000Market Cap$1.43 billion Next Earnings Date3/10/2020 (Estimated) OptionableOptionable Receive NBRV News and Ratings via Email Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NBRV Rates by TradingView Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions What is Nabriva Therapeutics' stock symbol? Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV." How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics PLC - (NASDAQ:NBRV) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.04. The biotechnology company had revenue of $6.92 million for the quarter, compared to analyst estimates of $1.23 million. Nabriva Therapeutics had a negative return on equity of 171.36% and a negative net margin of 910.45%. View Nabriva Therapeutics' Earnings History. When is Nabriva Therapeutics' next earnings date? Nabriva Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Nabriva Therapeutics. What price target have analysts set for NBRV? 6 brokerages have issued 12 month price objectives for Nabriva Therapeutics' shares. Their forecasts range from $2.00 to $13.00. On average, they anticipate Nabriva Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 396.8% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics. What is the consensus analysts' recommendation for Nabriva Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics. What are Wall Street analysts saying about Nabriva Therapeutics stock? Here are some recent quotes from research analysts about Nabriva Therapeutics stock: 1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (2/18/2020) 2. Northland Securities analysts commented, "We believe Xenleta is positioned to emerge as the 1st empiric monotherapy for treating CABP w/ potential global peak sales of $1B, supported by its significant clinical differentiation from existing therapies. Key Points Xenleta IV and Nabriva announced the FDA approval of Xenleta (lefamulin) IV and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) in adults. This represents the first approval of a new class antibiotic in nearly 2 decades. Xenleta is a semi-synthetic pleuromutilin that works via a unique mechanism of action by inhibiting the synthesis of bacteria protein necessary of proliferation." (8/16/2019) 3. HC Wainwright analysts commented, "We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 15.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at our $7 price target (representing risk-adjusted per share values of about $6.50 for lefamulin and about $0.50 for CONTEPO). Risks to the attainment of our PT include failure to obtain FDA approval, unforeseen safety and/or tolerability issues, commercial sales trajectory meaningfully below then consensus expectations, and the dilution to current shareholders from additional equity offering(s)." (8/18/2019) Has Nabriva Therapeutics been receiving favorable news coverage? Media coverage about NBRV stock has trended negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for Nabriva Therapeutics. Who are some of Nabriva Therapeutics' key competitors? Some companies that are related to Nabriva Therapeutics include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE) and Zai Lab (ZLAB). What other stocks do shareholders of Nabriva Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include Agile Therapeutics (AGRX), AcelRx Pharmaceuticals (ACRX), Zynerba Pharmaceuticals (ZYNE), Melinta Therapeutics (MLNT), SCYNEXIS (SCYX), Aduro BioTech (ADRO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Micron Technology (MU) and vTv Therapeutics (VTVT). Who are Nabriva Therapeutics' key executives? Nabriva Therapeutics' management team includes the folowing people: Mr. Steven P. Gelone, Pres & COO (Age 51)Dr. Colin Broom, Consultant & Director (Age 63)Mr. Gary L. Sender, Chief Financial Officer (Age 57)Mr. Theodore R. Schroeder, CEO & Director (Age 64)Mr. Thomas Lembck, Chief Information Officer Who are Nabriva Therapeutics' major shareholders? Nabriva Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (0.65%), Renaissance Technologies LLC (0.11%), Oxford Asset Management LLP (0.02%), Banco Bilbao Vizcaya Argentaria S.A. (0.02%), Clear Creek Financial Management LLC (0.01%) and Raymond James & Associates (0.00%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster, Steven P Gelone and Theodore R Schroeder. View Institutional Ownership Trends for Nabriva Therapeutics. Which institutional investors are selling Nabriva Therapeutics stock? NBRV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Barclays PLC and Wedbush Securities Inc.. Company insiders that have sold Nabriva Therapeutics company stock in the last year include Colin Md Broom, Gary Sender and Steven P Gelone. View Insider Buying and Selling for Nabriva Therapeutics. Which institutional investors are buying Nabriva Therapeutics stock? NBRV stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Oxford Asset Management LLP, Banco Bilbao Vizcaya Argentaria S.A., Clear Creek Financial Management LLC, Raymond James & Associates and Tower Research Capital LLC TRC . Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Theodore R Schroeder. View Insider Buying and Selling for Nabriva Therapeutics. How do I buy shares of Nabriva Therapeutics? Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Nabriva Therapeutics' stock price today? One share of NBRV stock can currently be purchased for approximately $1.51. How big of a company is Nabriva Therapeutics? Nabriva Therapeutics has a market capitalization of $1.43 billion and generates $9.66 million in revenue each year. The biotechnology company earns $-114,780,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. View Additional Information About Nabriva Therapeutics. What is Nabriva Therapeutics' official website? The official website for Nabriva Therapeutics is http://www.nabriva.com/. How can I contact Nabriva Therapeutics? Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected] MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 355 (Vote Outperform)Underperform Votes: 282 (Vote Underperform)Total Votes: 637MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/24/2020 by MarketBeat.com StaffFeatured Article: Balanced Fund
